0000950170-24-061258.txt : 20240516
0000950170-24-061258.hdr.sgml : 20240516
20240516182546
ACCESSION NUMBER: 0000950170-24-061258
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240514
FILED AS OF DATE: 20240516
DATE AS OF CHANGE: 20240516
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MacLean Michael F
CENTRAL INDEX KEY: 0001383731
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39321
FILM NUMBER: 24957200
MAIL ADDRESS:
STREET 1: 14 CAMBRIDGE CENTER
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Avidity Biosciences, Inc.
CENTRAL INDEX KEY: 0001599901
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 461336960
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10578 SCIENCE CENTER DRIVE
STREET 2: SUITE 125
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-401-7900
MAIL ADDRESS:
STREET 1: 10578 SCIENCE CENTER DRIVE
STREET 2: SUITE 125
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
FORMER COMPANY:
FORMER CONFORMED NAME: Avidity Biosciences LLC
DATE OF NAME CHANGE: 20161227
FORMER COMPANY:
FORMER CONFORMED NAME: Avidity NanoMedicines LLC
DATE OF NAME CHANGE: 20140211
4
1
ownership.xml
4
X0508
4
2024-05-14
0001599901
Avidity Biosciences, Inc.
RNA
0001383731
MacLean Michael F
C/O AVIDITY BIOSCIENCES, INC.
10578 SCIENCE CENTER DRIVE, SUITE 125
SAN DIEGO
CA
92121
false
true
false
false
Chief Financial Officer
true
Common Stock
2024-05-14
4
M
false
75000
8.82
A
119093
D
Common Stock
2024-05-14
4
S
false
75000
28.2806
D
44093
D
Stock Option (Right to Buy)
8.82
2024-05-14
4
M
false
75000
0
D
2030-05-14
Common Stock
75000
169427
D
The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 23, 2023.
This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $28.11 to $28.60. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
All unexercised shares subject to the option are fully vested and exercisable as of the date hereof.
/s/ John W. Wallen III, Ph.D., J.D., Attorney-in-Fact
2024-05-16